- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07732270
Evaluation of a Paraclinical Test for the Diagnosis of Arterial Insufficiency in Diabetic Patients With Foot Ulcers (INFLUX-D)
Evaluation of a Paraclinical Test for the Diagnosis of Arterial Insufficiency in Diabetic Patients With Foot Ulcers : INFLUX-D Study
The number of people living with diabetes has quadrupled worldwide since 1990, and more than 4.5 million people in France have diabetes. This chronic disease is a major cause of blindness, kidney failure, myocardial infarction, stroke, and lower-limb amputation. In France, in 2013, the incidence rates of hospitalizations for lower-limb amputation and diabetic foot ulcer among people with diabetes were 252 per 100,000 and 668 per 100,000 individuals with diabetes, respectively.
The management of diabetic foot disease requires a multidisciplinary approach involving general practitioners, diabetologists, dietitians, podiatrists, physiotherapists, and nurses. Nurses working in diabetic foot clinics, wound care centers, and community settings play a key role throughout the continuum of care for people with diabetes. Their responsibilities include prevention, patient education, clinical monitoring, and wound management. When one or more warning signs are identified, nurses promptly alert the physician to ensure early management of infection and timely referral to the appropriate healthcare professional(s).
One of the major factors contributing to impaired wound healing and ultimately leading to amputation in people with diabetes is arterial insufficiency. This condition is most commonly caused by peripheral artery disease (PAD), which is characterized by progressive atherosclerotic obstruction of the arteries supplying the lower limbs and represents a major cardiovascular disease. In patients with diabetes, PAD differs from atherosclerotic disease in non-diabetic individuals not only because of its higher prevalence but also because of its earlier onset, its frequently asymptomatic course, its predominantly distal distribution involving the infrapopliteal and even below-the-ankle arteries, and its greater severity.
The reference standard for diagnosing arterial insufficiency in patients with diabetes relies on quantitative microcirculatory assessment performed by vascular specialists. These investigations are based on arterial Doppler ultrasound and combine ankle and toe pressure measurements. The ankle-brachial index (ABI), the standard diagnostic test for PAD in non-diabetic patients, has limited reliability in individuals with diabetes because medial arterial calcification frequently renders the arteries incompressible. In contrast, toe pressure measurements can be performed in virtually all patients with diabetes who have intact toes. In selected cases, transcutaneous oxygen pressure (TcPO₂) measurement may also provide valuable additional information.
The availability of these investigations depends on access to vascular specialists, as a comprehensive vascular assessment may take up to two hours and varies according to local clinical practice and available resources.
Portable handheld vascular Doppler devices equipped with an 8-MHz probe are now available at an affordable cost and can be readily used in diabetic foot clinics, wound care centers, and community-based practices.
We hypothesize that this medical device, which assesses the overall hemodynamic status of the lower limb, could serve as a first-line screening tool for patients with diabetes presenting with a foot wound. This rapid assessment could facilitate early identification of patients requiring further vascular investigations by a vascular specialist when no arterial blood flow is detected.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Cécile Duchiron, Project Manager
- Numéro de téléphone: +33 5 46 68 45 67
- E-mail: cecile.duchiron@ght-atlantique17.fr
Lieux d'étude
-
-
France
-
La Rochelle, France, France, 17000
- Groupe Hospitalier de La Rochelle Ré Aunis
-
Contact:
- Cécile Duchiron, Project Manager
- Numéro de téléphone: +33 5 46 68 45 67
- E-mail: cecile.duchiron@ght-atlantique17.fr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Patient aged ≥18 years,
- Patient with type 1 or type 2 diabetes,
- Patient with a foot ulcer on one or both feet, regardless of the duration of diabetes (each limb will be considered hemodynamically independent, as the vast majority of arterial lesions in patients with diabetes are located below the inguinal ligament),
- Participant affiliated with or beneficiary of a social security scheme,
- Written informed consent obtained from the participant and the investigator no later than the day of inclusion and before any study-specific procedure
Exclusion Criteria:
- Patient with suspected distal thromboembolic disease of the lower limbs,
- Patient with suspected non-atherosclerotic peripheral arterial disease of the lower limbs (Buerger's disease, cannabis-associated arteriopathy, vasculitis, etc.),
- Patient who has previously undergone a revascularization procedure,
- Patient with an acute form of lower limb peripheral arterial occlusive disease,
- Patient with severe sepsis,
- Patient with no remaining great toes,
- Person under enhanced protection, including minors, persons deprived of liberty by judicial or administrative decision, and adults under legal protection,
- Pregnant and/or breastfeeding women,
- Patient unable to provide informed consent,
- Patient refusing to participate
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Experimental group
Use of a handheld Doppler to detect blood flow in the great toe(s)
|
Use of a handheld Doppler to detect blood flow in the great toe(s)
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Sensitivity
Délai: 7 days
|
Sensitivity of the handheld Doppler compared with the reference standard
|
7 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Specificity
Délai: 7 days
|
Specificity, defined as the proportion of diabetic feet in which blood flow in the great toe was detected by the foot clinic nurses and for which no arterial insufficiency was confirmed by the vascular physician's assessment (true negatives, TN), among diabetic feet for which the reference standard (microcirculatory tests) performed by the vascular physician showed no arterial insufficiency (TN + false positives, FP)
|
7 days
|
|
Number of limbs with a positive or negative Doppler blood flow test at the great toe, according to the nurse's assessment at the beginning and at the end of the nursing assessment.
Délai: 1 day
|
1 day
|
|
|
Number of limbs with a positive or negative Doppler blood flow test at the great toe, as assessed independently by two foot clinic nurses. The two nurses will be blinded to each other's assessment results
Délai: 1 day
|
1 day
|
Collaborateurs et enquêteurs
Les enquêteurs
- Directeur d'études: Frédérique DUENGLER, Study Director, Groupe Hospitalier de La Rochelle Ré Aunis
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- P02039
- 2026-A01497-44 (Autre identifiant: ANSM)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .